• Fetck KC Callout
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspective
Weekly Newscast
dvm360 Insights™
dvm360 LIVE!™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Client Handouts
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2022 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Drug for human overdoses treats sea turtles with brevetoxicosis

February 17, 2022
dvm360 Staff

This new study revealed that when sea turtles are treated with intravenous lipid emulsion, they experience a 94% survival rate.

A recent research paper1 published by the Morris Animal Foundation-funded researchers from Loggerhead Marinelife Center (LMC) has revealed that therapy used to treat human drug overdoses—intravenous lipid emulsion (ILE)—is effective in treating sea turtles suffering from toxic red tide exposure.

According to an organizational release,2 red tides are caused by an algal species that discharges potent neurotoxins, known as brevetoxins, into encompassing water. Brevetoxins bind to fats and exposure to the toxins results in neurological symptoms in impacted animals such as muscle spasming and disorientation. This process causes mass strandings and the deaths of various marine animals, including sea turtles.

“Red tides are not going away,” said Justin Perrault, PhD, the study’s principal investigator, in the release.2 “They’re getting more intense, they last longer, and we now see them every year. ILE therapy can help us successfully treat more sea turtles suffering from brevetoxicosis.”

ILE therapy works by placing a needle into a turtle’s neck and dripping the lipid emulsion directly into the turtle's bloodstream. This treatment causes the brevetoxins to combine with these lipids that are then removed safely from the body.

Traditional therapies used for brevetoxicosis include standard and supportive care (SSC) and/or dehydration therapy which was proven to be less effective and slow-acting compared to ILE therapy. For instance, survival rates for turtles just given SSC were 47%. Meanwhile, the rate increased to 94% when they received ILE therapy.1 Additionally, nearly all symptoms cleared within 24 to 48 hours after turtles received ILE treatment versus when using SSC, symptom elimination could take up to 7 days.1

What's more, ILE has been used to treat sea birds impacted by brevetoxins as well, with promising results.

“This study will have a significant positive impact on the treatment of sea turtles affected by red tides,” said Janet Patterson-Kane, BVSc, PhD, FRCVS, Morris Animal Foundation chief scientific officer, in the release.2 “The results also lay the groundwork for ILE use in other animal species suffering from brevetoxicosis.”

ILE therapy was initially used in human medicine for drug overdose cases because it was demonstrated to have a positive effect clearing the body of lipid-soluble drugs (eg, cocaine) as well as numerous antidepressants and anti-psychotics.

References

  1. Perrault JR, Barron HW, Malinowski CR, Milton SL, Manire CA. Use of intravenous lipid emulsion therapy as a novel treatment for brevetoxicosis in sea turtles. Sci Rep. 2021; 11. doi: 10.1038/s41598-021-03550-y
  2. Intravenous lipid solution saves sea turtles from red tide toxin. News release. Morris Animal Foundation. February 17, 2022. Accessed February 17, 2022.

Related Content:

Exotic Animal MedicineClinicalMedicalRolesAssociates
Mini donkey successfully receives pacemaker to manage fatal heart condition
Mini donkey successfully receives pacemaker to manage fatal heart condition
Dr Mike Nolan receives 2022 AVMF/EveryCat Health Foundation Research Award
Dr Mike Nolan receives 2022 AVMF/EveryCat Health Foundation Research Award
Acupuncture therapy in pets
Acupuncture therapy in pets

Latest News

Mini donkey successfully receives pacemaker to manage fatal heart condition

News wrap-up: This week’s headlines, plus Cincinnati Zoo welcomes baby hippo

Dr Mike Nolan receives 2022 AVMF/EveryCat Health Foundation Research Award

Lear's macaw reintroduced into wild and flourishing

View More Latest News